Clinical Trials Logo

Erysipelas clinical trials

View clinical trials related to Erysipelas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02902822 Completed - Melanoma Clinical Trials

Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo

Start date: October 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the validity and utility of a tele-dermatology system in the midterm periodic screening of non-widespread skin lesions of recent onset or for which a specialized early classification is deemed to change the prognosis - including precancerous skin lesions as well as melanoma and non-melanoma skin cancers - compared to control visits at fixed follow-up.

NCT ID: NCT01519778 Completed - Cellulitis Clinical Trials

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Start date: February 15, 2012
Phase: Phase 2
Study type: Interventional

Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.

NCT ID: NCT00552799 Completed - Clinical trials for Cellulitis/Erysipelas of the Leg

RCT to Investigate if Prophylactic Antibiotics Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg

PATCH1
Start date: July 2006
Phase: Phase 4
Study type: Interventional

To assess whether a period of prophylactic penicillin after an episode of cellulitis of the leg reduces the risk of repeat episodes. Participants are randomised to receive 12 months of prophylaxis (penicillin VK 250mg b.d. or placebo). The PATCH I study will recruit only patients with recurrent disease.

NCT ID: NCT00295178 Completed - Cellulitis Clinical Trials

Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas

Start date: February 20, 2006
Phase: Phase 4
Study type: Interventional

This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: - Time to erythema margin cessation to progress - Time to defervescence - Time to hospital discharge following relief of the presenting cellulitis or erysipelas - Degree of improvement of the following signs and symptom of cellulitis or erysipelas including - Degree of improvement of cellulitis-related pain and swelling as reported by subjects Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.